Generex Biotechnology Corporation, the leader in drug delivery for metabolic diseases through the inner lining of the mouth, has received notice of issuance of a patent on its Ii-Key peptide technology in China. This expands a solid intellectual property estate that includes both broad claims covering its technology as well as specific Ii-Key-containing drug development compounds. Additionally, management is actively seeking potential joint venture/licensing partnerships for its peptide cancer vaccine technology platform and is in active discussions with several large pharmaceutical companies.
The company recently reported interim results from a phase-II trial of an Ii-Key modified peptide vaccine for patients treated for breast cancer who are at high risk of relapse. While there was a 7% relapse rate in the control arm there were no relapses in the Ii-Key peptide arm (AE37) when analyzed at the 13-month time point. A review article co-authored by Eric von Hofe, president of Antigen Express entitled 'A New Era in Anticancer Peptide Vaccines', appeared in the journal Cancer, published by the American Cancer Society.
Anna Gluskin, president and chief executive officer of Generex, stated "We are pleased to have received this broad based patent in China for this important peptide vaccine technology. We believe the recently published results from our phase-II breast cancer study demonstrates the enormous potential our platform has for the treatment of this disease. We have begun active discussions with several large pharmaceutical companies for potential joint ventures and licensing agreements to significantly further our commercialization efforts in this area. We are confident that with the right partnerships this technology can have a far reaching positive impact on the treatment many types of cancers and we intend to aggressively pursue our goal of bringing this platform to the commercialization stage."
Generex is engaged in the research, development and commercialization of drug delivery systems and technologies.